Personnel Moves Archives - Page 5 of 42

Artificial heart maker BiVacor names Axonics CEO as chair of its board

New BiVacor Chair Raymond W. Cohen. [Image from Axonics]BiVacor announced today that it appointed Axonics CEO Raymond W. Cohen as the new chair of its board of directors.

Cohen serves as CEO and as a member of the board at Axonics, which develops sacral neuromodulation technologies. He originally founded Axonics in 2013 and took the Irvine, California-based company public in October 2018. The long-time executive has more than 40 years of experience in the life sciences industry.

In addition to his roles at Axonics, Cohen serves as an independent director of SoniVie. The clinical-stage, venture-backed company develops denervation technology for uncontrolled hypertension.

Cohen now heads up the board at BiVacor, a company making a total artificial heart (BTAH). BiVacor received FDA investigational device exemption (IDE) for the artificial heart last month. It’s now set to conduct a first-in-human clinical feasibility study evaluating the use of the syst…

Bioventus names Medtronic, J&J veteran as CEO

Bioventus (Nasdaq:BVS) announced that it appointed Robert Claypoole as its new president and CEO, effective Jan. 10, 2024.

Claypoole succeeds Anthony Bihl, who served as interim CEO and board director since April 2023. Bihl took over in the interim role after Ken Reali stepped down for unknown reasons after three years in the corner office.

Durham, North Carolina-based Bioventus said in a news release that Claypoole brings more than 20 years of global commercial leadership experience in the medical device industry. He most recently served as EVP at Mölnlycke Health Care AB, leading its global wound care business.

Previously, Claypoole held senior positions at Medtronic, Covidien and Johnson & Johnson.

“We are excited to have Rob join Bioventus and build upon the significant improvements made this year to further elevate our execution and overall performance,” said William A. Hawkins, Bioventus’ executive chair. “Throughout his career, Rob has …

Merit Medical founder, CEO to retire in 2025

Fred Lampropoulos, Merit Medical founder, president and CEO.

Merit Medical Systems (Nasdaq:MMSI) announced that Fred Lampropoulos, its founder, CEO and president, intends to retire in two years.

The company outlined its ongoing CEO succession plan process with an amended and restated employment agreement. Lampropoulos intends to continue to serve as president and CEO through Dec. 31, 2025.

To carry out its CEO succession responsibilities, the Merit board appointed a special steering committee of independent directors. Ann Millner serves as lead independent director of the committee overseeing the plan in preparation for the CEO’s retirement.

According to a news release, Merit plans to prepare the company for a CEO transition “at the appropriate time.” It enlisted executive search firm Korn Ferry to assist the board in identifying potential internal and external candidates.

Merit said it doesn’t intend to provide further upd…

Former J&J MedTech head Ashley McEvoy takes board role at consumer goods giant

Ashley McEvoy [Image courtesy of Procter & Gamble]Less than two months after announcing her departure from Johnson & Johnson MedTech, Ashley McEvoy has taken on a role on the board of Procter & Gamble.

In October, the former EVP and worldwide chair at J&J MedTech announced her intention to leave the world’s second-largest medical device manufacturer. Tim Schmid took over the position from McEvoy, who spent 27 years at J&J. The reason behind her departure was “to pursue new opportunities,” she said.

While the seasoned medtech executive has yet to share any planned C-level moves, she has a new position on the board at a major consumer goods company in Procter & Gamble. Her appointment to the company’s board of directors went into effect on Dec. 12.

Over the course of her time at J&J, McEvoy most recently led the MedTech unit and spearheaded efforts to develop integrated, digitized solutions. She brought the busine…

BCI maker Synchron adds former Dexcom CEO to its board

Andy Rasdal [Image courtesy of Synchron]Brain-computer interface (BCI) developer Synchron announced today that it appointed medtech veteran Andy Rasdal to its board of directors.

Rasdal brings more than 30 years of experience in developing and commercializing novel medical devices. He previously served as CEO of Dexcom, a leader in the continuous glucose monitor (CGM) space. There, he led the company through FDA approval and a successful IPO on the way to commercializing its CGM technology.

Currently, Rasdal serves as executive chair of Epitel, which develops a wearable, wireless EEG system to detect seizure conditions. He also led Obalon through FDA approval, an IPO and the commercialization of an obesity product as founding CEO.

Other previous roles include president of Medtronic’s Vascular unit. Rasadal also served as VP of global marketing at Arterial Vascular Engineering, which Medtronic bought for $4.3 billion. He also held positions at EP Techn…

CMR Surgical has a new chief commercial officer

Massimiliano Colella. [Image courtesy of CMR Surgical]Surgical robot technology developer CMR Surgical announced today that it named Massimiliano Colella as its chief commercial officer (CCO).

In the new role, Colella oversees the commercial and marketing operations at the Cambridge, UK-based company. It marks another C-suite appointment for CMR Surgical, which earlier this year appointed Supratim Bose as its new CEO.

Colella offers experience in the medical device industry and a senior leadership background in the hospital providers sector. His appointment comes as CMR Surgical accelerates its commercial installations of the Versius surgical robot.

Versius is a small-scale system with collaborative arms and bedside units for direct patient access. It also features freedom of port placement to best suit the needs of each patient. CMR Surgical designed Versius to enable surgeons to perform more minimal access surgery. Its minimally invasive approach assists …

AdvaMed picks GE HealthCare CEO Peter Arduini as new chair, forms medical imaging division

Peter Arduini is now the chair of the AdvaMed board of directors. [Photo courtesy of GE HealthCare]AdvaMed today announced the appointment of GE HealthCare CEO Peter Arduini as its board chair as it establishes a medical imaging division.

Arduini takes over the board chair spot from former Johnson & Johnson MedTech head Ashley McEvoy. McEvoy resigned from her position at J&J in October and subsequently stepped down as AdvaMed chair less than a year into a two-year term.

“The timing of Peter Arduini’s election as our new chair couldn’t be better,” AdvaMed President and CEO Scott Whitaker said in a news release. “His leadership of GE HealthCare, a global leader in medical imaging, pharmaceutical diagnostics and digital solutions, will provide strategic insight and direction to AdvaMed as we work to ensure an aligned and inclusive focus across companies in every sector of medtech.”

As the medtech advocacy organization named Arduini to lead…

The biggest medtech personnel moves of 2023

Johnson & Johnson MedTech Worldwide Chair Tim Schmid [Photo courtesy of Johnson & Johnson]The leadership change at Johnson & Johnson MedTech will go down as the year’s biggest personnel move in medtech, barring a December surprise.

In October, J&J EVP and J&J MedTech Worldwide Chair Ashley McEvoy announced her resignation from the world’s second-largest device manufacturer. She’s staying on into the first quarter of 2024 while her successor, Tim Schmid, gets settled into his new role.

Schmid, a 30-year J&J vet who was most recently company group chair of J&J MedTech Asia Pacific, said he’s “committed to building even further on the progress we’ve already made.”

“While I recognize that we have more work to do, I’m focused on further advancing our impact and our competitiveness,” he said this month. “Our goal is clear. It is to be No. 1 or No. 2 in every market that we compete.”

Here…

Hologic promotes from within to fill COO spot

Essex Mitchell. [Image from Hologic]Hologic (NYSE: HOLX) + announced that it promoted Essex Mitchell to the role of chief operating officer, effective Jan. 1, 2024.

Mitchell, 44, originally joined Hologic in September 2017 as VP of sales and commercial excellence for the GYN surgical decision. He currently serves as president of GYN surgical solutions, a post he assumed in August 2020. Mitchell brings almost 20 years of medical device and pharmaceutical experience to the COO spot at Hologic.

From September 2006 to September 2017, he held various commercial roles of increasing responsibility at Stryker. Mitchell led Stryker’s sales and marketing efforts across multiple divisions during his tenure. Prior to his medtech career, Mitchell played professional football in both the National and Canadian Football leagues.

In connection with his promotion, the Hologic board approved an increase in Mitchell’s base…

Distalmotion has a new CEO

New CEO Greg Roche. [Image courtesy of Distalmotion]Distalmotion announced that it appointed Greg Roche as its CEO as the company looks to continue commercial expansion for its surgical robot.

The company also named Roche to its board of directors. In his role, Roche will lead U.S. and European expansion initiatives for the Dexter surgical robot, helping with the next phase of Distalmotion’s growth.

“We are incredibly proud to welcome Greg to Distalmotion’s leadership team,” said Rick Anderson, Distalmotion board chair. “Greg’s global experience in the space, proven U.S. launch track record and depth of understanding of our market segment is an extraordinary fit and sets the company up for a very exciting future.”

Roche joins Distalmotion with more than 20 years of commercial and executive experience in the medtech industry. His background spans laparoscopic surgery, endoscopic visualization and surgical robotics. Most recently, Roche served as CEO of…

Caldera Medical appoints new CFO

[Image courtesy of John Pitstick’s LinkedIn]Caldera Medical this week announced it appointed John Pitstick as chief financial officer and executive VP of corporate development.

The company said the appointment will allow it to focus on advancing Caldera’s position in the women’s health sector with M&A activity during rapid expansion.

Pitstick began his career at Ernst & Young managing a global client base and contributing to several IPOs. Most recently, he was CFO of Dyve Biosciences. He has also served as CFO of Seven Lakes Technologies and Conversant.

As CFO of Caldera Medical, Pitstick’s experience in leading mergers and acquisitions will be pivotal, the company said. His experience includes overseeing transactions exceeding $3 billion and has successfully raised over $1 billion in financing. Caldera has ambitious expansion plans, including strategic acuqisionts to enhance the company’s portfolio and market presence,…

Orthofix has a new CEO

LimaCorporate CEO Massimo Calafiore

Orthofix Medical (Nasdaq: OFIX) + announced today that it named Massimo Calafiore as its new president and CEO.

Lewisville, Texas-based Orthofix expects the appointment of Calafiore to go into effect in early 2024. He currently serves as CEO of LimaCorporate and will take over the corner office at Orthofix following the completion of Lima’s acquisition by Enovis. The company also expects him to join its board of directors.

Calafiore’s appointment comes following a major upheaval at Orthofix earlier this year. After the company opened the year with a massive merger with SeaSpine, in September, it terminated a trio of executives with cause. The company cut ties with CEO Keith Valentine, CFO John Bostjancic and chief legal officer Patrick Keran following an investigation.

An independent outside legal counsel conducted the investigation and Orthofix’s independent direc…